Abstract: A display device includes a display panel including a pixel and a sensor pixel, the pixel including a light emitting element and a driving transistor controlling a current flowing through the light emitting element, the sensor pixel including sensor transistors, a data driver that supplies a data signal to the pixel through a data line and provides a sensor data signal to the sensor pixel through a sensor data line, and a sensing driver that obtains sensing information on a current flowing through the sensor pixel. The sensor transistors are electrically connected in parallel to each other and are commonly electrically connected to the sensor data line. The sensor transistors and the driving transistor include a substantially same characteristic.

Abstract: Embodiments provide a display device that includes a substrate, a transistor disposed on the substrate, and a light emitting device that is electrically connected to the transistor. The light emitting device includes a first electrode that is electrically connected to the transistor, a second electrode disposed on the first electrode, a light emitting layer disposed between the first electrode and the second electrode, a hole transport layer disposed between the first electrode and the light emitting layer, and an electron blocking layer disposed between the hole transport layer and the light emitting layer. Mobility of the hole transport layer is equal to or less than about 2.0*10?3 cm2/(Vs), and a real part of impedance of the light emitting device is equal to or less than about 100?, in a frequency range of about 105 Hz to about 106 Hz.

Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Abstract: It is disclosed a blood glucose prediction system and method using saliva-based artificial intelligence deep learning technique.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.